This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Aceragen Valuation

Is V9Z undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of V9Z when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate V9Z's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate V9Z's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for V9Z?

Key metric: As V9Z is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for V9Z. This is calculated by dividing V9Z's market cap by their current revenue.
What is V9Z's PS Ratio?
PS Ratio	0.4x
Sales	US$7.33m
Market Cap	US$3.12m

V9Z key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5x
Enterprise Value/EBITDA	-1.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does V9Z's PS Ratio compare to its peers?

The above table shows the PS ratio for V9Z vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.6x
PA8 Paion	0.2x	30.2%	€2.6m
CNW co.don	0.7x	n/a	€6.5m
ECX Epigenomics	1.8x	n/a	€616.0k
2INV 2invest	7.9x	n/a	€60.9m
V9Z Aceragen	0.4x	n/a	€2.9m

Price-To-Sales vs Peers: V9Z is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (12.2x).

Price to Sales Ratio vs Industry

How does V9Z's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	7.9x	21.6%
V9Z Aceragen	0.4x	n/a	US$3.12m
BIO3 Biotest	1.3x	-4.1%	US$1.42b
CNW co.don	0.7x	n/a	US$6.97m

7 Companies		Estimated Growth	Market Cap
Industry Avg.	7.9x	39.7%
V9Z Aceragen	0.4x	n/a	US$3.12m

No more companies

Price-To-Sales vs Industry: V9Z is good value based on its Price-To-Sales Ratio (0.4x) compared to the European Biotechs industry average (9.8x).

Price to Sales Ratio vs Fair Ratio

What is V9Z's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

V9Z PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate V9Z's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Pharming Group

€498.9m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

-1.0%

-32.7%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.46

-3.4%

2.1%

Merck

US$249.2b

Operates as a healthcare company worldwide.

6MK

US$93.10

-1.0%

-0.1%